Rash management for anti-EGFR antagonist
Kiyohara, Y.
Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 3): 526-531
2011
ISSN/ISBN: 0047-1852 PMID: 22214016 Document Number: 649129
Document emailed within 1 workday
Related Documents
Fox, L.P. 2006: Pathology and management of dermatologic toxicities associated with anti-EGFR therapy Oncology 20(5 Suppl 2: 26-34Cunningham, M.P.; Thomas, H.; Marks, C.; Green, M.; Fan, Z.; Modjtahedi, H. 2008: Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells International Journal of Oncology 33(5): 1107-1113
Shepherd, F.A. 2016: Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients Clinical Advances in Hematology and Oncology: H&o 14(1): 41-43
Soeda, H.; Shimodaira, H.; Ishioka, C. 2011: Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(7): 1079-1083
Sandler, A.B. 2006: Nondermatologic adverse events associated with anti-EGFR therapy Oncology 20(5 Suppl. 2): 35-40
Cirillo, M.; Lombardi, C.; Chiricone, D.; Bilancio, G.; Marcarelli, F.; De Santo, N.G. 2008: Early identification of kidney disease by eGFR: what is the prevalence of eGFR in the population? Journal of Nephrology 21(Suppl 13): S102-S106
Hirano, S.; Takeda, Y.; Hiraishi, Y.; Higashino, M.; Nakamichi, S.; Ishii, S.; Naka, G.; Iikura, M.; Izumi, S.; Sugiyama, H.; Kobayashi, N. 2012: Efficacy of combination therapy with EGFR-TKi and cytotoxic drug in lung adenocarcinoma already treated with EGFR-TKi Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(2): 213-219
Yano, S.; Kondo, K.; Yamaguchi, M.; Richmond, G.; Hutchison, M.; Wakeling, A.; Averbuch, S.; Wadsworth, P. 2003: Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition Anticancer Research 23(5a): 3639-3650
Jin, B.; Zhang, Y.; Zhang, X.; Li, R.; Lou, Y.; Niu, Y.; Huang, A.; Han, B. 2014: Value of carcinoembryonic antigen levels in predicting the efficacy of EGFR-TKi in advanced non-small cell lung cancer harboring EGFR mutations Zhonghua Yi Xue Za Zhi 94(30): 2327-2331
El Hamdani, W.; Amrani, M.; Attaleb, M.; Laantri, N.; Ennaji, M.M.; Khyatti, M.; El Mzibri, M. 2010: EGFR, p16INK4a and E-cadherin immuno-histochemistry and EGFR point mutations analyses in invasive cervical cancer specimens from Moroccan women Cellular and Molecular Biology 56 Suppl: Ol1373-Ol1384
Li, J.; Hong, Q.; Zhang, X.; Hu, J.; Bai, C. 2014: Therapeutic efficacy and safety of chemotherapy subsequent EGFR-TKi in advanced non-small cell lung cancer patients with EGFR-TKi acquired resistance Zhonghua Yi Xue Za Zhi 94(30): 2342-2345
Shimodaira, H.; Komine, K.; Soeda, H.; Ishioka, C. 2010: Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(5): 795-798
Osera, S.; Shitara, K. 2013: II. which is the better choice for second- line treatment?; BEV or anti-EGFR after BEV treatment in patients with unresectable wild type K-ras colon cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(11): 1459
Urata, Y.; Satouchi, M. 2015: I. what is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer? Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(8): 931-934
Scollo-Lavizzari, G. 1988: The clinical anti-convulsant effects of flumazenil, a benzodiazepine antagonist European Journal of Anaesthesiology. Suppl 2: 129-138
Litovchick, A.; Lapidot, A.; Eisenstein, M.; Kalinkovich, A.; Borkow, G. 2001: Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities Biochemistry 40(51): 15612-15623
Hopf, R.; Drews, H.; Kaltenbach, M. 1984: Anti-angina effect of gallopamil in comparison with another calcium antagonist and a placebo Zeitschrift für Kardiologie 73(9): 578-585
Pendley, C.E.; Fitzpatrick, L.R.; Capolino, A.J.; Davis, M.A.; Esterline, N.J.; Jakubowska, A.; Bertrand, P.; Guyon, C.; Dubroeucq, M.C.; Martin, G.E. 1995: RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat Journal of Pharmacology and Experimental Therapeutics 273(3): 1015-1022
Liu, H.-A.; Sun, H.-X.; Mo, X.-M.; Li, S.-Y.; Li, X.-Y.; Zhang, G.; Lu, L. 2012: Anti-HCMV and KSHV effect of a trapping ligand antagonist for herpesvirus-encoded GPCR Indian Journal of Experimental Biology 50(5): 313-319
Maslov, L.N.; Krylatov, A.V.; Lishmanov, I.B. 1997: The anti-arrhythmic effect of the selective sigma-receptor antagonist DuP 734 [1-(cyclopropylmethyl)-4-(2'-(4''-fluorophenyl)-2'-oxoethyl)piper idine HBr Eksperimental'naia i Klinicheskaia Farmakologiia 60(2): 24-26